Article

Genentech, Alcon among ‘Best Companies to Work For’

New York-Fortune magazine has named Genentech and Alcon Laboratories to its latest “100 Best Companies to Work For” list.

New York-Fortune magazine has named Genentech and Alcon Laboratories to its latest “100 Best Companies to Work For” list.

South San Francisco, CA-based Genentech, with almost 11,000 employees in the United States, is fifth in the 2008 rankings. The achievement marks the company’s 10th consecutive year on the list, a distinction that cannot be claimed by any other biotechnology company, according to Genentech.

This year marks Alcon Laboratories’ 10th consecutive time on the list, too. The company, with almost 6,000 employees in the United States, ranks 60th on the 2008 list, five spots up from last year. Alcon Laboratories noted that Fortune cited the company’s retirement program, which matches employee contributions 2.4:1, as well as its benefits package, financial compensation, and U.S. headquarters campus in Fort Worth, TX.

Fortune worked with the Great Place to Work Institute to compile the list. About 1,500 firms were contacted, and 406 participated. Two-thirds of a company’s score was based on responses from a minimum of 400 randomly selected employees to a 57-question survey of their attitudes about management’s credibility, job satisfaction, and camaraderie. The other one-third of each score was based on a company’s responses to a “culture audit” that included detailed questions about compensation and benefit programs as well as a series of open-ended questions about hiring practices, methods of internal communication, training, recognition programs, diversity efforts, and other issues.

The full list appears in the Feb. 4 issue of Fortune and is available at www.fortune.com/bestcompanies.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) NeuroOp Guru: Using OCT to forecast outcomes in ethambutol optic neuropathy
(Image credit: Ophthalmology Times) Inside NYEE’s new refractive solutions center with Kira Manusis, MD
(Image credit: Ophthalmology Times) Dilsher Dhoot, MD, on the evolution of geographic atrophy therapy: where are we now?
(Image credit: Ophthalmology Times Europe) Anat Loewenstein, MD, shares insights on the real-world results of remote retinal imaging
(Image credit: Ophthalmology Times) Two-wavelength autofluorescence for macular xanthophyll carotenoids with Christine Curcio, PhD
(Image credit: Ophthalmology Times) FLIO and the brain: Making the invisible visible with Robert Sergott, MD
(Image credit: Ophthalmology Times) Structure-function correlates using high-res OCT images with Karl Csaky, MD, PhD
(Image credit: Ophthalmology Times) SriniVas Sadda, MD, on high-res OCT of atrophic and precursor lesions in AMD
(Image credit: Ophthalmology Times) Christine Curcio, PhD, shares histology update supporting review software and revised nomenclature for <3 μm OCT
© 2025 MJH Life Sciences

All rights reserved.